3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9 Olaparib Intermediate Factory

3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid  CAS: 61260-15-9 Purity: ≥98.0% Appearance: White or Almost White Powder Intermediate of Olaparib (CAS: 763113-22-0) PARP-Inhibitor High Quality, Commercial Production Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.High Purity, Commercial Production Olaparib and Related Intermediates: Olaparib CAS 763113-22-0 2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7 1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8 3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
Item Specifications
Appearance White or Almost White Powder
Purity ≥98.0%
Moisture (K.F) ≤0.50%
Total Impurities ≤2.0%
Test Standard Enterprise Standard
Usage Intermediate of Olaparib (CAS: 763113-22-0) PARP-Inhibitor

Description:

Specifications:

Package & Storage:

Chemical Name 3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid
Synonyms Dimethyl 3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonate 
CAS Number 61260-15-9
CAT Number RF-PI453
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H11O5P
Molecular Weight 242.17
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid (CAS: 61260-15-9), intermediate of Olaparib (CAS: 763113-22-0). Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours